Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsFRA:QDI +1.43%73 EV-to-EBIT is 19.59 as of Jul. 30, 2026, which is 27% above its 10-year median of 15.44. GuruFocus rates FRA:QDI with a GF Score™ of 73/100 and a GF Value™ of €168.90 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Quest Diagnostics ranks better than 56.73% on this metric.
The historical rank and industry rank for Quest Diagnostics's EV-to-EBIT or its related term are showing as below:
FRA:QDI'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.79 Med: 15.44 Max: 19.42
Current: 19.19
During the past 13 years, the highest EV-to-EBIT of Quest Diagnostics was 19.42. The lowest was 6.79. And the median was 15.44.
FRA:QDI's EV-to-EBIT is ranked better than 56.73% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.78
vs FRA:QDI: 19.19
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Quest Diagnostics's Enterprise Value for the quarter that ended in Jun. 2026 was €25,706 Mil.
Quest Diagnostics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics EV-to-EBIT Related Terms
Quest Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Quest Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's EV-to-EBIT falls into.
Quest Diagnostics's current Enterprise Value is €28,194 Mil.
Quest Diagnostics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (FRA:QDI) has a EV-to-EBIT of 19.59 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest Diagnostics and its competitors. This is 27% above median its historical median of 15.44. Over the past decade, Quest Diagnostics' EV-to-EBIT has ranged from 6.79 to 19.42. According to the industry distribution chart, Quest Diagnostics ranks #45 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 43.3%.
Is Quest Diagnostics' EV-to-EBIT too high?
Quest Diagnostics' current EV-to-EBIT of 19.59 is 27% above median its 10-year median of 15.44. Over the past 10 years, this metric has ranged from a low of 6.79 to a high of 19.42. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.78. Quest Diagnostics' value of 19.59 is 14% below this industry median. Based on the distribution chart, Quest Diagnostics ranks #45 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' EV-to-EBIT compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #45 out of 104 companies for EV-to-EBIT. This puts Quest Diagnostics in the upper half of its industry. The industry median EV-to-EBIT is 22.78. Quest Diagnostics' value of 19.59 is 14% below this benchmark. Historically, Quest Diagnostics' own EV-to-EBIT has ranged from 6.79 to 19.42 over the past decade. While the company's 10-year median is 15.44 vs. the industry median of 22.78, Quest Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.78, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current EV-to-EBIT of 19.59 is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current EV-to-EBIT is 19.59, which is 27% above median its own 10-year median of 15.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €168.90, compared to a current price of €206.00 — trading 22% above its estimated fair value. The current EV-to-EBIT is 19.59, which is 27% above median its 10-year median of 15.44 and 14% below the Medical Diagnostics & Research industry median of 22.78. Quest Diagnostics' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current EV-to-EBIT is 19.59 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €206.00 is trading 22% above its estimated GF Value™ of €168.90.
GuruFocus considers Quest Diagnostics to be Modestly Overvalued.
Key valuation signals for FRA:QDI:
EV-to-EBIT: 19.59 (27% above median its 10-year median of 15.44)
GF Value™: €168.90 vs. price of €206.00 (22% above fair value)
Industry Position: 14% below the Medical Diagnostics & Research median (#45 of 104)
No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
73GF Score
Get the complete analysis for FRA:QDI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QDI has been successfully added to your 
